Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Amiodarone pulmonary toxicity

INTRODUCTION

Amiodarone is an iodinated benzofuran derivative that is used to suppress ventricular and supraventricular tachyarrhythmias. (See "Clinical uses of amiodarone".)

Pulmonary toxicity is among the most serious adverse effects of amiodarone. Several forms of pulmonary disease occur among patients treated with amiodarone, including interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome (ARDS), diffuse alveolar hemorrhage (DAH), pulmonary nodules and solitary masses, and also (rarely) pleural effusion. Other adverse effects from amiodarone include photosensitivity, blue-gray discoloration of the skin, thyroid dysfunction, corneal deposits, abnormal liver function tests, and bone marrow suppression [1].

The types, pathogenesis, risk factors, diagnosis, and treatment of amiodarone pulmonary toxicity will be reviewed here. The other major side effects of amiodarone are discussed separately. (See "Major side effects of amiodarone".)

INTERSTITIAL PNEUMONITIS

Interstitial pneumonitis is the most common presentation of amiodarone-induced pulmonary disease. Interstitial pneumonitis usually presents after two or more months of therapy, especially in patients in whom the dose of amiodarone exceeds 400 mg per day [2]. The incidence of pulmonary toxicity from amiodarone is not precisely known; it is estimated to be 1 to 5 percent, depending on the dose of amiodarone [3-6]. The rate increases at higher doses of amiodarone, particularly over 500 mg daily.

Pathology — The histopathologic findings of amiodarone-induced interstitial pneumonitis include a nonspecific interstitial pneumonitis (with a mononuclear cell infiltrate), type II cell hyperplasia, interstitial edema, fibrosis, and lipid-laden alveolar macrophages [7]. The presence of numerous lipid-laden, "foamy" macrophages in the air spaces is a characteristic finding in all patients exposed to amiodarone (picture 1). The "foamy" appearance is due to amiodarone-phospholipid complexes (image 1) and is also seen in patients without lung toxicity who are taking amiodarone. Amiodarone can cause an accumulation of phospholipids within lysosomes in other lung cells, although this is less common [1,7]. Ultrastructural studies show myelinoid (lamellated) inclusion bodies in the affected tissue.

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Aug 20, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Mason JW. Amiodarone. N Engl J Med 1987; 316:455.
  2. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988; 93:1067.
  3. Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol 2011; 108:705.
  4. Papiris SA, Triantafillidou C, Kolilekas L, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010; 33:539.
  5. Schwaiblmair M, Berghaus T, Haeckel T, et al. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 2010; 99:693.
  6. Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwartz MI, King TE Jr. (Eds), People's Medical Publishing House, Shelton, CT 2011. p.637.
  7. Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol 1997; 1:47.
  8. Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. Am J Surg Pathol 2012; 36:509.
  9. Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003; 123:646.
  10. Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988; 93:1242.
  11. Seki S, Itagaki S, Kobayashi M, et al. Amiodarone increases the accumulation of DEA in a human alveolar epithelium-derived cell line. Biol Pharm Bull 2008; 31:1449.
  12. Yano T, Itoh Y, Yamada M, et al. Combined treatment with L-carnitine and a pan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lung epithelial cells. Apoptosis 2008; 13:543.
  13. Lee KY, Oh S, Choi YJ, et al. Activation of autophagy rescues amiodarone-induced apoptosis of lung epithelial cells and pulmonary toxicity in rats. Toxicol Sci 2013; 136:193.
  14. Kosseifi SG, Halawa A, Bailey B, et al. Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ther Adv Respir Dis 2009; 3:289.
  15. Nikaido A, Tada T, Nakamura K, et al. Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. Int J Cardiol 2010; 140:328.
  16. Akoun GM, Gauthier-Rahman S, Milleron BJ, et al. Amiodarone-induced hypersensitivity pneumonitis. Evidence of an immunological cell-mediated mechanism. Chest 1984; 85:133.
  17. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008; 66:82.
  18. Range FT, Hilker E, Breithardt G, et al. Amiodarone-induced pulmonary toxicity--a fatal case report and literature review. Cardiovasc Drugs Ther 2013; 27:247.
  19. Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89:896.
  20. Pfeil MN, Vollenweider P, Fitting JW. Fatal pulmonary toxicity after a short course of amiodarone therapy. Clinical Geriatrics 2012; 20:34.
  21. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51.
  22. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.
  23. Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007; 71:1610.
  24. Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 1997; 30:514.
  25. Olshansky B, Sami M, Rubin A, et al. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005; 95:404.
  26. Endoh Y, Hanai R, Uto K, et al. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 2000; 86:229.
  27. Kohno N, Yokoyama A, Kondo K. KL-6 as a serum marker for amiodarone-induced pulmonary toxicity. Intern Med 2000; 39:1004.
  28. Bernal Morell E, Hernández Madrid A, Marín Marín I, et al. Multiple Pulmonary Nodules and Amiodarone. KL-6 as a New Diagnostic Tool. Rev Esp Cardiol (Engl Ed) 2005; 58:447.
  29. Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 1987; 87:7.
  30. Standertskjöld-Nordenstam CG, Wandtke JC, Hood WB Jr, et al. Amiodarone pulmonary toxicity. Chest radiography and CT in asymptomatic patients. Chest 1985; 88:143.
  31. Oyama N, Oyama N, Yokoshiki H, et al. Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study. Circ J 2005; 69:466.
  32. Kuhlman JE, Teigen C, Ren H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990; 177:121.
  33. Hudzik B, Polonski L. Amiodarone-induced pulmonary toxicity. CMAJ 2012; 184:E819.
  34. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009; 16:43.
  35. Xaubet A, Roca J, Rodriguez-Roisin R, et al. Bronchoalveolar lavage cellular analysis and gallium lung scan in the assessment of patients with amiodarone-induced pneumonitis. Respiration 1987; 52:272.
  36. Ohar JA, Jackson F, Dettenmeier PA, et al. Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis. Chest 1992; 102:999.
  37. Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992; 102:1005.
  38. Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 2006; 99:383.
  39. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4:1250.
  40. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298:1312.
  41. Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989; 86:2.
  42. Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86:4.
  43. Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern Med 2006; 45:1303.
  44. De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf 2012; 11:1023.
  45. Grabczak EM, Zielonka TM, Wiwała J, et al. Amiodarone induced pneumonitis and hyperthyroidism: case report. Pol Arch Med Wewn 2008; 118:524.
  46. Sato S, Watanabe K, Ishida T, et al. [Amiodarone-induced pneumonitis associated with marked eosinophilia in BALF]. Nihon Naika Gakkai Zasshi 2006; 95:356.
  47. Valle JM, Alvarez D, Antúnez J, Valdés L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 1995; 8:470.
  48. Zitnik, RJ. Drug-induced lung disease: Antiarrhythmic agents. J Respir Dis 1996; 17:254.
  49. Schindler K, Schima W, Kaliman JF. Cryptogenic organizing pneumonia due to amiodarone: long-term follow-up after corticosteroid treatment. Wien Klin Wochenschr 2010; 122:511.
  50. Greenspon AJ, Kidwell GA, Hurley W, Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84:III407.
  51. Kay GN, Epstein AE, Kirklin JK, et al. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 1988; 62:490.
  52. Van Mieghem W, Coolen L, Malysse I, et al. Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105:1642.
  53. Wood DL, Osborn MJ, Rooke J, Holmes DR Jr. Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc 1985; 60:601.
  54. Beasley MB, Franks TJ, Galvin JR, et al. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002; 126:1064.
  55. Kumar S, Bangalore S, Kumari R, et al. Amiodarone-induced acute respiratory distress syndrome masquerading as acute heart failure. J Emerg Med 2012; 43:e311.
  56. Sato N, Kojima K, Horio Y, et al. Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. Chest 2013; 143:1146.
  57. Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987; 18:349.
  58. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994; 105:305.
  59. Borders CW 3rd, Bennett S, Mount C, Claassen SL. A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med 2012; 177:118.
  60. Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ 2010; 19:435.
  61. Azzam I, Tov N, Elias N, Naschitz JE. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J 2006; 82:73.
  62. Ruangchira-Urai R, Colby TV, Klein J, et al. Nodular amiodarone lung disease. Am J Surg Pathol 2008; 32:1654.
  63. Gonzalez-Rothi RJ, Hannan SE, Hood CI, Franzini DA. Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions. Chest 1987; 92:179.
  64. Uong V, Nugent K, Alalawi R, Raj R. Amiodarone-induced loculated pleural effusion: case report and review of the literature. Pharmacotherapy 2010; 30:218.
  65. Sheikhzadeh A, Schäfer U, Schnabel A. Drug-induced lupus erythematosus by amiodarone. Arch Intern Med 2002; 162:834.